ALLMedicine™ Bleeding Time Center
Research & Reviews 441 results
https://doi.org/10.1007/s40256-022-00536-7 10.1186/s13020-020-00320-2 10.2174/1573403X15666181205110624 10.3390/ijms21165717 10.1136/heartjnl-2020-316977 10.1016/j.acvd.2020.03.023 10.1016/j.ijcard.2014.11.182 10.2147/JBM.S41404 10.1016/j.jacc.2011.11.044 10.1016/j.jacc.2021.04.061 10.1056/NEJMoa1707278 10.1016/j.thromres.2020.11.010 10.1111/j.1540-8159.1995.tb06733.x 10.1093/eurheartj/ehy778 10.1007/s11239-019-01835-8 10.1055/a-1450-8178 10.1053/j.jvca.2021.02.029
American Journal of Cardiovascular Drugs : Drugs, Devices... Huang L, Yu Z et. al.
Jun 19th, 2022 - This study aimed to investigate the effectiveness and safety of idarucizumab for periprocedural cardiac tamponade after catheter ablation of atrial fibrillation (AF) in patients treated with dabigatran. We retrospectively studied 28 patients who r...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169676
Drug Design, Development and Therapy; Liu YB, Zhang L et. al.
Jun 10th, 2022 - Recombinant neorudin (EPR-hirudin, EH) was developed through the addition of an EPR (Glu-Pro-Arg) peptide to the amino terminus of hirudin, which can be recognized and cut by coagulation factors XIa (FXIa) and/or Xa (FXa). In this study, the low-b...
https://doi.org/10.2174/1871530322666220607124757
Endocrine, Metabolic & Immune Disorders Drug Targets; Akhter MS, Rashid H et. al.
Jun 9th, 2022 - Hematotoxicity is an underexplored end point of toxicity in most of the chemical exposures. An adverse effect on the hematological system arising out of xenobiotic exposure causes impaired hemostasis and coagulation leading to disease. BPA and ace...
https://doi.org/10.1002/micr.30926
Microsurgery Heitzer M, Ooms M et. al.
Jun 8th, 2022 - In free flaps, 5%-10% of complications are related to failure of sutured vascular anastomoses. Adhesive-based microvascular anastomoses are potential alternatives but are associated with failure rates of 70% in research studies. VIVO is a new adhe...
https://clinicaltrials.gov/ct2/show/NCT05232981
Jun 2nd, 2022 - This randomized control trial will be conducted at Tanta University hospital, Egypt, from 2022 to 2024. Tanta University Hospital is considered the main tertiary hospital at the center of Nile Delta . Cases, suspected to have PAS, are recruited fr...
Guidelines 1 results
https://doi.org/10.1016/j.thromres.2009.08.005
Thrombosis Research; Cosmi B, Alatri A et. al.
Sep 11th, 2009 - SYNOPSIS OF RECOMMENDATIONS: The Italian Society for Thrombosis and Haemostasis (SISET: Società Italiana per lo Studio dell' Emostasi e della Trombosi) promoted the development of a series of guidelines which would adopt evidence-based medicine me...
Drugs 35 results see all →
Clinicaltrials.gov 57 results
https://clinicaltrials.gov/ct2/show/NCT05232981
Jun 2nd, 2022 - This randomized control trial will be conducted at Tanta University hospital, Egypt, from 2022 to 2024. Tanta University Hospital is considered the main tertiary hospital at the center of Nile Delta . Cases, suspected to have PAS, are recruited fr...
https://clinicaltrials.gov/ct2/show/NCT04588727
May 20th, 2022 - The study will provide data on safety, tolerability, PK, and PD of AZD3366 in healthy subjects. Three populations (healthy subjects, healthy Japanese subjects and healthy Chinese subjects) will be enrolled into this study. This study will be condu...
https://clinicaltrials.gov/ct2/show/NCT04090099
May 18th, 2022 - 99 patients will be included in the study. Group C (Control, n = 31), Group ES (Erector Spina, n = 31), Group PV (Paravertebral n = 31) will be randomized. A researcher will present the patient distribution to patients in a sealed envelope (1: 1: ...
https://clinicaltrials.gov/ct2/show/NCT05329285
May 18th, 2022 - Short background/ Rationale/Aim: CABG has been shown to prolong survival in patients with reduced left ventricular (LV) function and multi-vessel coronary artery disease and "CABG is recommended as the first revascularization strategy choice in pat...
https://clinicaltrials.gov/ct2/show/NCT05351203
May 10th, 2022 - This is a randomized controlled study designed to include 50 patients aged from 18 to 65 years old undergoing lumbar spine surgeries. fifty patients meeting the inclusion criteria will be randomly assigned into two equal groups: Group A(n=25): cau...
News 14 results
https://www.medscape.com/viewarticle/911977
Apr 18th, 2019 - A new approach to inhibiting platelets that may separate the antithrombotic effect from the bleeding risk has shown promising preliminary results, raising the hope of developing an agent for the treatment of acute ischemic stroke that can inhibit ...
https://www.staging.medscape.com/viewarticle/911977
Apr 18th, 2019 - A new approach to inhibiting platelets that may separate the antithrombotic effect from the bleeding risk has shown promising preliminary results, raising the hope of developing an agent for the treatment of acute ischemic stroke that can inhibit ...
https://www.medscape.com/viewarticle/888744
Dec 11th, 2017 - Hello and welcome. I am Dr George Lundberg, and this is At Large at Medscape. Most lab tests that are ordered do not need to be done. The results are either normal, negative, or show no change from the previous test. Why do them? I admit that ther...
https://www.mdedge.com/hematology-oncology/article/185637/thrombosis/preventing-thrombosis-without-increasing-bleeding-risk
HT Staff
Jun 1st, 2017 - Photo by Aaron Logan Lab mice It may be possible to disrupt thrombosis without increasing the risk of bleeding, according to preclinical research published in Nature Communications. “We have found a new thrombosis target that does not increase ble.
https://www.mdedge.com/hematology-oncology/article/186946/thrombosis/antiplatelet-agent-may-pose-lower-risk-bleeding
HT Staff
Jan 5th, 2017 - Cynomolgus macaque Photo by Sakurai Midori Researchers say they have developed an antiplatelet agent that has demonstrated considerable antithrombotic activity and low bleeding liability in monkeys. The agent, known as BMS-986120, is a PAR4 antago.
